Hagar ElGhazawy, Consultant of Clinical Oncology of Breast Cancer Unit, Faculty of Medicine at Ain Shams University, shared a post on LinkedIn:
“From evidence to experience, and from clinical trials to real-world practice — I truly enjoyed diving into the discussion on the best sequencing of T-DXd vs. Tucatinib in HER2+ metastatic breast cancer with brain metastases.
It was a pleasure to share this case discussion with my dear friend Dr Hazem EL Mansy at the inspiring Breast Cancer Summit hosted by Astra.
Always grateful for opportunities to exchange thoughts alongside dear professors, collegues, and friends, bringing science closer to patients.”
More posts featuring Breast Cancer.
